FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
AbCellera Biologics Inc. (NASDAQ:ABCL) announced the results of its Annual Meeting of Shareholders held on June 12, 2025, in a recent SEC filing. The company, a leader in pharmaceutical preparations, reported that its shareholders voted on several key proposals during the meeting.
The first proposal involved the election of two Class II directors, Carl L. G. Hansen, Ph.D., and Michael Hayden, MBCHB (M.D.), Ph.D., for a three-year term expiring in 2028. Shareholders approved the election with 141,233,414 votes in favor of Dr. Hansen and 121,224,143 votes for Dr. Hayden. There were 444,265 and 417,794 votes against them, respectively, and abstentions of 6,760,498 and 26,796,240, respectively. Additionally, there were 33,560,807 broker non-votes.
The second proposal was to ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. This proposal also passed with 183,078,982 votes for, 678,941 against, and 241,151 abstentions.
The third proposal, known as Say-on-Pay, was a non-binding advisory vote to approve the compensation of the company’s named executive officers. Shareholders showed their support with 131,605,595 votes for, 16,469,354 against, and 363,228 abstentions. There were 35,560,807 broker non-votes for this proposal as well.
No other matters were voted on at the Annual Meeting. The details of the proposals and the voting results were outlined in the company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2025.
This SEC filing indicates shareholder confidence in the company’s leadership and financial oversight as AbCellera continues its operations in the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.